Arrowhead Pharmaceuticals has received authorisation from Health Canada for its siRNA medicine, Redemplo, for adults with FCS ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Skye Bioscience Inc. (NASDAQ:SKYE) shares gained 5.3% in premarket trading on Monday after the company revealed a ...

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

Halozyme Therapeutics (HALO) and Skye Bioscience (SKYE) announced the companies entered into a non-exclusive global collaboration and license ...

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, today announced the availability of two new products: insulin glargine-yfgn ...